ReviewF1000Research2018
Early clearance versus control: what is the meaning of a negative tuberculin skin test or interferon-gamma release assay following exposure to
Review in F1000Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 19 citations in OpenAlex.
- Route of BCG administration determines success.Human vaccines & immunotherapeutics · 2026Review
- Feasibility of ending tuberculosis in Shangrao City through active intervention measures: a mathematical study.Frontiers in public health · 2025Article
- Recombinant mycobacterial DNA-binding protein 1 with post-translational modifications boosts IFN-gamma production from BCG-vaccinated individuals' blood cells in combination with CpG-DNA.Scientific reports · 2024Article
- Comparative immune responses toiScience · 2023Article
- The spectrum of tuberculosis described as differential DNA methylation patterns in alveolar macrophages and alveolar T cells.Clinical epigenetics · 2022Article
- Immunological basis of early clearance of Mycobacterium tuberculosis infection: the role of natural killer cells.Clinical and experimental immunology · 2021Review
- Towards new TB vaccines.Seminars in immunopathology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The elimination of tuberculosis (TB) cannot reasonably be achieved by treatment of individual cases and will require an improved vaccine or immunotherapy. A challenge in developing an improved TB vaccine has been the lack of understanding what is needed to generate sterilizing immunity against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.